Oral Olorofim Eyes AmB-Sparing Niche But Pivotal Proof Still Missing

Olorofim Shows Promise for Invasive Aspergillosis with Renal Safety

Olorofim demonstrated promising results in a trial for second-line invasive aspergillosis (IA), with a notable benefit in renal safety. This oral antifungal is positioned as a potentially safer alternative to amphotericin B (AmB), which is currently used. Given these positive findings, olorofim is anticipated to receive FDA approval for IA in 2027. Mould-active azole antifungals (MAAs) are currently the standard of care for IA.

• Olorofim's trial findings are promising, particularly highlighting its renal safety. This is a significant advantage, as it addresses a key concern with existing treatments like amphotericin B (AmB), which can have renal toxicity. The drug's oral administration also offers a more convenient and potentially safer alternative for patients requiring second-line treatment for invasive aspergillosis.
• The drug is seen as having strong potential for FDA approval in 2027. This projection is based on the urgent need for an orally administered, safer treatment option for invasive aspergillosis, suggesting a favorable regulatory pathway and significant market opportunity if approved.
• While mould-active azole antifungals (MAAs) remain the standard of care for invasive aspergillosis, olorofim is being evaluated as a second-line treatment. Its potential as a safer, orally administered alternative to amphotericin B could shift treatment paradigms, especially for patients who cannot tolerate or do not respond to MAAs or require a less toxic option than AmB.

The Urgent Need for Safer Oral Options in IA

Invasive aspergillosis (IA) remains associated with high morbidity and mortality, with mortality of nearly 100% without adequate treatment. Early initiation of effective systemic antifungal treatment is essential for successful outcome, yet clinical clues for diagnosis are sparse and early microbiological proof is rare. Current options are further constrained by resistance, variable drug exposure, and toxicity.

• Emerging azole resistance driving treatment failure: In a clinical collection of 519 A. fumigatus isolates, frequency of itraconazole resistance was 5%, with 65% (22) cross-resistant to voriconazole and 74% (25) cross-resistant to posaconazole; 8 infections failed therapy (progressed), and 5 failed to improve (remained stable). Resistance mechanisms include cyp51A substitutions including TR/L98H, G54W, M220I, F219C, and TR34/L98H/T289A/Y121F, with detection complicated by mostly negative fungal cultures; detection of resistance-associated mutations was associated with azole treatment failure in 6/8 patients with a RAM compared with 12/45 patients without RAMs (P = 0.01), and 6 week mortality was 50.0% versus 18.6% (P = 0.07).

• High pharmacokinetic variability and need for therapeutic drug monitoring with voriconazole: Voriconazole exhibits saturable metabolism, nonlinear kinetic profile, drug interactions, and wide interpatient variability influenced by CYP2C19 genotype, with 46% of patients having lack of response when trough plasma concentrations were less than or equal to 1 microg/mL, compared with 12% with trough concentrations greater than 1 microg/mL (p = 0.02). The recommended standard dose (200 mg twice a day) resulted in significant plasma concentrations (>0.5 mg/L) in 20% of cystic fibrosis lung transplant patients, requiring higher doses (average 570 +/- 160 mg/day, +43%, P<0.01), while most studies recommend trough concentrations of approximately 1-6 microg/mL and target concentrations (1-5.5 μg/ml); in ICU patients, one-third of isavuconazole trough concentrations were below the target of 1 mg/L.

• Dose-limiting toxicities of first-line and alternative agents: Voriconazole adverse effects include visual disturbances (21%) and elevations in liver transaminase levels (12.4%), with greater incidence associated with trough concentrations greater than 6 microg/mL, plus neurologic effects (14%) and hepatic abnormalities (30%); symptoms of visual disturbances and hallucinations appeared within 1 week and resolved upon discontinuation or dose reduction, with trough concentrations exceeding 5 μg/mL. High-dose liposomal amphotericin B (10 mg/kg daily) was associated with infusion-related reactions in 3 patients, 2-fold increase in serum creatinine in 4 of 17 patients (23%) versus 1 of 15 patient (7%) with combination therapy, and hypokalemia <3 mmol/L in 3 patients and 2 patients, respectively.

• Delayed diagnosis, breakthrough infection, and prognostic burden: Delayed diagnosis and therapy may lead to poor outcomes, with breakthrough IA occurring despite mold-active prophylaxis and diagnosis difficult due to low sensitivities of mycological tests; galactomannan screening showed false positive reactivity in 8 patients (10.2%), with significant association between false positive GM (= or > 0.5) and administration of piperacillin-tazobactam (p < 0.01). Elevated baseline serum galactomannan levels independently predicted treatment non-response (p = 0.039) and 12-week all-cause mortality (p < 0.001), dual-source positivity linked to reduced treatment response (22% vs. 43%, p = 0.01) and higher IA-attributable mortality (52% vs. 27%, p = 0.002), and overall mortality was 40% in cerebral aspergillosis and 20% (n = 1) in isolated cerebral aspergillosis in immunocompetent patients.

Olorofim's Promising Renal Safety in Invasive Aspergillosis

Published safety data characterize olorofim as showing good tolerability in patients with few or no treatment options, with hepatic biochemistry elevation identified as the main treatment-emergent safety signal. Events were generally managed to resolution by liver enzyme monitoring and dose modification, reduction, pause, or discontinuation.

• In the single-arm, open-label, phase 2b study in 203 treated patients with invasive fungal disease, medically significant liver enzyme elevations adjudicated to be at least possibly due to olorofim occurred in 20 (10%) of 203 patients and were managed to resolution by dose modification in 14 (7%) patients or by discontinuation of treatment in six (3%).

• In 41 patients with disseminated coccidioidomycosis with limited or no treatment options, the main treatment-emergent adverse event was hepatic biochemistry elevation in 9 of 41 patients (21.9%), which was managed by liver enzyme monitoring and dose reduction or pause in 8 patients (19.5%) and drug discontinuation in 1 patient (2.4%).

• Gastrointestinal intolerance occurred in 20 (10%) patients in the overall phase 2b population, predominantly reported as mild or moderate and self-limiting, and there were no treatment-related deaths.

• A case report in a 67-year-old man treated with olorofim for refractory disseminated coccidioidomycosis described an acute, almost 30-fold increase in liver enzymes in a hepatocellular pattern after administration of olorofim, followed by a rapid downtrend over the next few weeks, with rechallenge at a reduced dose not reproducing the transaminase elevations, consistent with a probable Roussel-Uclaf Causality Assessment Method score of 8.

• In the Phase 2 salvage therapy analysis, the rate of drug-induced liver injury was not increased in patients receiving combination with an azole, and in a French compassionate-use cohort of 17 patients with refractory invasive mold infections, no severe adverse events were reported.

Olorofim's Potential to Reshape IA Treatment

Caspofungin, a lipopeptide, is an antifungal drug that belong to the class of echinocandin. It inhibits fungal cell wall β-(1,3)-glucan synthase activity and is the second-line of drug for invasive aspergillosis, a fatal infection caused mainly by Aspergillus fumigatus. Enfumafungin is a natural triterpene glycoside also with a β-(1,3)-glucan synthase inhibitory activity and reported to have antifungal potential. Caspofungin initially inhibited the growth of A. fumigatus, but the effect was lost over time. By contrast, Enfumafungin inhibited this fungal growth for the duration investigated.

Both Caspofungin and Enfumafungin caused a decrease in the cell wall β-(1,3)-glucan content with a compensatory increase in the chitin, and to a minor extent they also affected cell wall galactose content. Treatment with these two antifungals did not result in the exposure of β-(1,3)-glucan on A. fumigatus mycelial surface. Enzymatic digestion suggested a modification of β-(1,3)-glucan structure, specifically its branching, upon Enfumafungin treatment. While there was no difference in the immunostimulatory capacity of antifungal treated A. fumigatus conidia, alkali soluble-fractions from Caspofungin treated mycelia weakly stimulated the dendritic cells, possibly due to an increased content of immunosuppressive polysaccharide galactosaminogalactan. Enfumafungin not only inhibits β-(1,3)-glucan synthase activity, but also causes modifications in the structure of β-(1,3)-glucan in the A. fumigatus cell wall.

Voriconazole is the first line treatment for invasive aspergillosis. In solid organ transplant recipients with proven/probable IA treated for ≥48 h with isavuconazole (n = 57) or voriconazole (n = 77) as first-line therapy, there were no differences in the rate of 12-wk clinical response between the ISA and VORI groups (59.6% versus 59.7%, respectively; odds ratio [OR], 0.99; 95% CI, 0.49-2.00). This result was confirmed after propensity score adjustment (OR, 0.81; 95% CI, 0.32-2.05) and matching (OR, 0.79; 95% CI, 0.31-2.04). All-cause and IA-attributable mortality were also similar. Patients in the ISA group were less likely to experience treatment-emergent adverse events (17.5% versus 37.7%; P = 0.011) and premature treatment discontinuation (8.8% versus 23.4%; P = 0.027). Clinical trial results showing the non-inferiority of isavuconazole to voriconazole for all-cause mortality further support its positioning relative to voriconazole.

Olorofim: A New Oral Frontier Against Resistant Aspergillosis

Invasive aspergillosis (IA) remains a formidable challenge, particularly in immunocompromised patients, with high mortality rates. The current therapeutic landscape is constrained by significant limitations. Mould-active azole antifungals, while a cornerstone of therapy, face an escalating threat from widespread azole resistance in Aspergillus fumigatus, both in clinical and environmental settings. This resistance is linked to specific cyp51A gene mutations and is associated with treatment failure and increased mortality. Meanwhile, amphotericin B, a potent broad-spectrum agent, is often limited by its significant nephrotoxicity, necessitating careful monitoring and often restricting its use.
The emergence of olorofim, an orotomide with a novel mechanism of action targeting dihydroorotate dehydrogenase (DHODH), represents a crucial advancement. Its promising trial results in second-line IA, particularly its notable renal safety profile, position it as a potentially safer and effective oral alternative to amphotericin B. This is especially significant for patients who cannot tolerate or have failed azole therapy, offering a much-needed new pathway to combat resistant infections. However, the journey is not without its considerations. While olorofim offers a distinct mechanism, studies indicate that resistance can still emerge through specific DHODH mutations, and cross-resistance with agricultural DHODH inhibitors has been observed, underscoring the need for continuous surveillance. Furthermore, the evolving antifungal pipeline includes other novel agents that could introduce future competition. Despite its efficacy against early biofilm formation, mature Aspergillus fumigatus biofilms have shown reduced susceptibility to olorofim, suggesting potential challenges in certain clinical scenarios. Nevertheless, olorofim's anticipated FDA approval in 2027 signals a pivotal moment, offering a new class of antifungal that could significantly broaden the therapeutic options and improve outcomes for patients battling this life-threatening infection.